Astellas Seeks To Block Fresenius Generic Adenoscan

Law360, Washington (December 13, 2012, 4:00 PM EST) -- Astellas Pharma US Inc. slapped the generic drugmaker Fresenius Kabi USA LLC with a patent infringement suit in Delaware federal court Wednesday, crying foul at the company's application to market a generic version of its cardiac imaging agent Adenoscan.

Fresenius notified Astellas on Oct. 29 that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration to produce a generic adenosine injection, which replicates the stress placed on the heart during strenuous activity to allow for cardiac stress testing in patients...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.